First Choice Neurology

First Choice Neurology Research Center 32 Clinical Trials

First Choice Neurology Research Center 32 offers clinical trials for Complex Regional Pain Syndrome, Migraines, Alzheimer’s disease, Hypotension, Multiple Sclerosis, Parkinson’s disease, Epilepsy, and other neurological disorders.

clinical trials

Interventional:

Grunenthal

This is a 1-year clinical trial, investigating Neridronic Acid in the form of an infusion for the treatment of Complex Regional Pain Syndrome. There will be 4 infusions over the course of 10 days, with the possibility of a second course of infusions at the 6-month mark. Patients must show CRPS symptoms for 2 years or less and have also failed at least 2 prior therapies.

 

Allergan

This is a 6-month clinical trial, investigating Atogepant for the prevention of Migraines in patients with Episodic Migraine. Patients must be 18 to 80 years of age, have 4 to 14 probable migraine headache days per month and have a migraine onset age of less than 50.

 

TRIAD by Avanir

This is a 12-week clinical trial, investigating d6-DM/Q for the treatment of agitation in patients with dementia of the Alzheimer’s type. Patients must be between 50 and 90 years of age and have a MMSE score of 6 to 26.

 

RESTORE by Lundbeck

This is a 9-month clinical trial, investigating Droxidopa for Symptomatic Neurogenic Orthostatic Hypotension. Patients must have a documented drop of 20 mmHg in Systolic Blood Pressure, within 3 minutes of standing.

ALITHIOS by Novartis

This is a 5-year clinical trial, investigating the long-term safety and tolerability of Ofatumumab in patients with Relapsing Multiple Sclerosis. Patients must have participated in a Novartis MS trial using Ofatumumab as ALITHIOS is an open-label extension trial to its predecessor.

 

Observational:

BRAIN by UCB

This is a 1-year clinical trial, investigating the retention of patients using Brivaracetam for the treatment of epilepsy.

 

INSYTE by Acadia

This is a 3-year clinical trial, investigating the effectiveness of antipsychotic therapies and other treatment approaches in the management of Parkinson’s Disease Psychosis.

 

Genzyme

This is a 10-year clinical trial, investigating the necessary duration of monitoring in patients using Lemtrada for the treatment of Multiple Sclerosis.

 


Contact First Choice Neurology Research Center 32

Neurology Office of South Florida, LLC
9970 Central Park Blvd., Suite 207
Boca Raton, FL 33428
Phone: (561) 482-1027
Fax: (561) 482-1028

Providers:
Brian Costell, MD
Michelle Ferreira, DO
Meghan Jacobs, PsyD
Irvine Mason, MD
Carol Eickhorn, ARNP

Contact:
Cody Paauwe, CRC
(561) 482-1027 ext. 9
cpaauwe@fcneurology.net

Translate »